Loading
Life sciences · Journal article
Nar Cancer · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Deficiencies in DNA repair pathways create context-specific vulnerabilities that may be exploited therapeutically. Recent studies have established EXO1 as a druggable nuclease, but the genetic contexts that confer sensitivity to EXO1 inhibition remain incompletely defined. Here, we assessed whether pharmacological inhibition of EXO1 selectively targets repair-deficient cancer cells across multiple DNA repair backgrounds. Using potent and selective EXO1 inhibitors, we demonstrate impaired viability in cells deficient for Fanconi Anaemia pathway components (FANCG and APITD1/MHF1), BRCA1-A complex factor BRCC36, and the spliceosome factor ZRSR2. EXO1 inhibition in FANCG or ZRSR2 KO cells induced accumulation of micronuclei, γH2AX, and RPA32 phosphorylation at serine 33, consistent with enhanced replication stress leading to cell death, and supporting a role for EXO1 in processing replication-associated DNA structures and maintaining genome stability under conditions of replication stress. Combining EXO1 inhibitor with PARP inhibitors exacerbated cytotoxicity, suggesting partially nonoverlapping repair functions and therapeutic potential for EXO1/PARP inhibitor combination strategies. Collectively, these findings establish that pharmacological inhibition of EXO1 recapitulates the sensitivity to genetic EXO1 loss in certain DNA repair deficient backgrounds, supporting its development as a targeted therapeutic strategy in molecularly stratified cancers.